7 Facts About Phosphatidylserine and What the Evidence Actually Shows for Menopause Cognitive Decline
The brain fog that comes with perimenopause is one of the cruelest parts of the transition — losing words, blanking on names you've known for decades, feeling like your own mind has gone slightly foggy. When something like phosphatidylserine gets passed around in menopause forums as a fix, it's tempting to want it to be true. The honest answer is: it might help the edges, but it is not going to replace what estrogen was doing. Knowing that up front saves a lot of money and a lot of misplaced hope.
Learn more about Rose →Phosphatidylserine Is a Structural Fat Your Brain Already Makes — Until It Doesn't
Phosphatidylserine (PS) is a phospholipid that makes up roughly 15% of the fat content in the brain, concentrated in neuronal cell membranes where it helps regulate the fluidity and signaling function of those membranes. The body synthesises it, but production declines with age, and the brain becomes increasingly dependent on dietary sources — primarily fatty fish, organ meats, and soy or sunflower lecithin. This decline in endogenous PS is one reason researchers began studying supplementation in the context of age-related cognitive changes.
The FDA's Qualified Health Claim Sounds Impressive — But 'Qualified' Is Doing a Lot of Work
In 2003, the FDA allowed a qualified health claim that PS 'may reduce the risk of dementia in the elderly,' and updated guidance in 2020 extended a similar qualified claim for PS and cognitive dysfunction more broadly. A qualified claim, however, means the evidence is suggestive but not conclusive — it is a lower bar than the FDA's standard health claim, which requires strong scientific agreement. Women researching PS online often encounter the claim as if it confirms efficacy, when in fact the FDA language explicitly states that the evidence is 'highly uncertain.'
The Strongest Clinical Evidence Comes From Older Adults With Already-Declining Cognition, Not Perimenopausal Women
The most frequently cited RCTs on PS — including the Crook et al. studies from the early 1990s — enrolled participants aged 50–75 with age-associated memory impairment or early Alzheimer's disease, not healthy middle-aged women experiencing hormonal transition. Results in those trials showed modest but statistically significant improvements in tasks like name-face recall and telephone number recall over 12 weeks. Extrapolating those findings to perimenopause cognitive symptoms, which have a different underlying mechanism (estrogen withdrawal rather than general neurodegeneration), is a meaningful scientific leap that the current evidence base does not support cleanly.
Estrogen and PS Are Not Doing the Same Job — and One Cannot Simply Replace the Other
Estrogen has wide-ranging neuroprotective effects: it supports acetylcholine synthesis, promotes dendritic spine density, modulates serotonin and dopamine signalling, and reduces neuroinflammation — mechanisms that collectively explain much of the cognitive disruption women experience during perimenopause. Phosphatidylserine primarily supports membrane fluidity and facilitates neurotransmitter release, particularly of acetylcholine and dopamine, which gives it some overlapping territory. But PS does not address declining oestradiol levels, does not regulate hypothalamic-pituitary function, and has no documented effect on the hormonal fluctuations that drive perimenopausal brain fog specifically.
PS May Help With Cortisol-Driven Cognitive Symptoms — and That Is Actually Relevant to Menopause
One of the better-replicated effects of PS is blunting the cortisol and ACTH response to physical and psychological stress, documented in trials using 400–800mg per day in healthy adults. This is relevant to perimenopause because elevated and dysregulated cortisol is common during the transition, and high cortisol directly impairs working memory and verbal recall by suppressing hippocampal function. If a woman's cognitive symptoms are being compounded by stress and poor sleep — both extremely common in perimenopause — there is a plausible physiological rationale for PS providing modest support, even if the direct menopause-cognition evidence is thin.
The Source of PS in Supplements Matters — Bovine Cortex Versus Soy or Sunflower Lecithin
The original clinical trials were conducted with PS derived from bovine (cow) brain cortex, which has a fatty acid profile closely matching human brain PS and was consistently bioactive in trials. Concerns about bovine spongiform encephalopathy (BSE) prompted a shift to plant-derived PS from soy or sunflower lecithin in virtually all commercial supplements from the mid-1990s onward. Plant-derived PS has a different fatty acid structure and has shown more mixed results in subsequent trials — some studies show benefit, others show no significant effect — so direct comparisons to the original bovine-based research need to be made cautiously.
The Evidence Floor Is Honest: PS Is Not Harmful, Not a Cure, and Probably Not Useless
PS has a good safety profile at standard doses (100–300mg per day of soy-derived PS), with no serious adverse effects documented in trials up to six months, and it is generally well tolerated in adults without blood-thinning medications, which it may potentiate at higher doses. For women in perimenopause experiencing cognitive symptoms, the realistic expectation from the evidence is modest support for memory retrieval and stress-related cognitive blunting — not a restoration of pre-perimenopausal sharpness. The most evidence-supported intervention for menopause-specific cognitive symptoms remains hormone therapy in appropriate candidates, and PS should be considered a possible adjunct rather than an alternative.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.